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Abstract Acquired copper deficiency has been recogni-
sed as a rare cause of anaemia and neutropenia for over half
a century. Copper deficiency myelopathy (CDM) was only
described within the last decade, and represents a treatable
cause of non-compressive myelopathy which closely
mimics subacute combined degeneration due to vitamin
B12 deficiency. Here, 55 case reports from the literature
are reviewed regarding their demographics, aetiology,
haematological and biochemical parameters, spinal imag-
ing, treatment and outcome. The pathophysiology of dis-
orders of copper metabolism is discussed. CDM most
frequently presented in the fifth and sixth decades and was
more common in women (F:M = 3.6:1). Risk factors
included previous upper gastrointestinal surgery, zinc
overload and malabsorption syndromes, all of which impair
copper absorption in the upper gastrointestinal tract. No
aetiology was established in 20% of cases. High zinc levels
were detected in some cases not considered to have pri-
mary zinc overload, and in this situation the contribution of
zinc to the copper deficiency state remained unclear.
Cytopenias were found in 78%, particularly anaemia, and a
myelodysplastic syndrome may have been falsely diag-
nosed in the past. Spinal MRI was abnormal in 47% and
usually showed high T2 signal in the posterior cervical and
thoracic cord. In a clinically compatible case, CDM may be
suggested by the presence of one or more risk factors and/
or cytopenias. Low serum copper and caeruloplasmin
levels confirmed the diagnosis and, in contrast to Wilson’s
disease, urinary copper levels were typically low. Treat-
ment comprised copper supplementation and modification
of any risk factors, and led to haematological normalisation
and neurological improvement or stabilisation. Since any
neurological recovery was partial and case numbers of
CDM will continue to rise with the growing use of bariatric
gastrointestinal surgery, clinical vigilance will remain the
key to minimising neurological sequelae. Recommenda-
tions for treatment and prevention are made.
Keywords Anaemia  Copper deficiency 
Spinal cord disease  Subacute combined degeneration 
Vitamin B12 deficiency
Introduction
Copper is a trace metal which acts as a prosthetic group in
several key enzymes and is thus essential for the structure
and function of the bone marrow and nervous system.
Acquired copper deficiency has long been recognised as a
cause of anaemia and, less commonly, other cytopenias
[11, 83]. It was only in 2001 that an association with
myelopathy was reported [71]. The clinical and radiologi-
cal picture is usually indistinguishable from subacute
combined degeneration due to vitamin B12 (cobalamin)
deficiency (SCD) [40, 44], and the syndrome is thought to
represent the human counterpart of swayback or enzootic
ataxia, a copper deficiency myelopathy (CDM) occurring
in ruminants [3]. Other, less frequently reported and less
clearly causally related neurological associations of
acquired copper deficiency include isolated peripheral
neuropathy [20, 86], motor neuron disease [84], myopathy
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[46], cerebral demyelination [65, 74], cognitive dysfunc-
tion [58, 77] and optic neuropathy [20, 74].
Patients typically present with gait difficulties, which
arise through sensory ataxia due to dorsal column dys-
function and to a lesser extent through spasticity. Paraes-
thesia in upper and lower limbs is common, whilst urinary
symptoms occur only in a minority. Examination usually
shows a spastic paraparesis or tetraparesis with a truncal
sensory level for dorsal column modalities. A sensory/
motor neuropathy frequently coexists and manifests as
depression of distal reflexes and superimposed sensory
impairment in a glove and stocking distribution.
A previous review has addressed the clinical features,
investigation findings and treatment outcomes in a series of
25 patients with CDM [38] (some of these cases were also
reported elsewhere [21, 39, 41, 42, 44–47]). An additional
30 cases of myelopathy or myeloneuropathy have now
been reported [1, 2, 4, 12, 13, 16, 18, 19, 21, 24, 28–30, 58,
63, 67, 71, 74, 77, 88, 89]. Here we review the published
cases with regards to their demographics, aetiology, labo-
ratory indices, spinal imaging, treatment and outcome.
Clinical features and neurophysiological data were exclu-
ded as the mode and quality of description varied greatly
between reports, and because they were already adequately
addressed in the previous review.
Methods
The PubMed database was searched from its inception to
August 2008 using the terms hypocupr* or copper in
combination with myelopathy, myeloneuropathy, com-
bined degeneration, subacute combined degeneration
(MeSH) or spinal cord diseases (MeSH). References in
relevant papers were reviewed for additional cases.
The following data were extracted for each case where
available: age, sex, primary aetiology, haematological
indices at presentation (haemoglobin, mean corpuscular
volume (MCV), white cell count, platelet count), bio-
chemical indices at presentation (serum copper, serum
caeruloplasmin, serum zinc, 24 h urinary copper and zinc),
spinal imaging findings, treatment and outcome.
The primary aetiology was classified as previous upper
gastrointestinal surgery, malabsorption, zinc overload, iron
supplements or unknown. Treatment was categorised by
dose and route of administration of copper supplements,
and any accompanying intervention such as cessation of
exogenous zinc supply. Outcome was divided into neuro-
logically improved, unchanged or unknown; there were no
reports of deterioration with adequate copper replacement.
Units were standardised to lg/mL for serum copper and
zinc and mg/dL for serum caeruloplasmin. Where figures
were given in molar quantities, the standard atomic weights
63.546 (copper) and 65.049 (zinc) were used to convert
into the corresponding mass unit. Urinary copper and zinc
excretion were converted to mg/24 h, but this was not
possible where figures were given as mass per unit volume.
Statistical analyses were performed using SPSS 14.0
(SPSS Inc., Chicago, Illinois).
Results
A total of 55 cases were found in the literature [1, 2, 4, 12,
13, 16, 18, 19, 21, 24, 28–30, 38, 39, 41, 42, 44–47, 58, 63,
67, 71, 74, 77, 88, 89]. Age at presentation ranged from 30
to 82 years with a peak in the fifth and sixth decades (mean
54 years, median 53 years; Fig. 1). There was a marked
female preponderance (female:male ratio 3.6:1).
Previous upper gastrointestinal surgery was the com-
monest reported cause, being implicated in almost half the
cases (47%, 26 cases; Table 1). Of these, 17 cases were
attributable to non-bariatric surgery, typically partial gas-
trectomy for peptic ulcer disease, with the remaining 9
being due to bariatric interventions, mostly Roux-en-Y
gastric bypass. The second commonest aetiology, zinc
overload (16%, 9 cases), was thought to be caused by the
use of denture cream (4 cases) or zinc supplements (2
cases), or by oversubstitution of zinc in the dialysate during
chronic haemodialysis (1 case). In the remaining 2 cases of
zinc overload no cause was found. Less common causes of
copper deficiency were malabsorption (15%, 8 cases), with
half of these being due to coeliac disease, and iron sup-
plements (2%, 1 case). In the remaining 20% (11 cases), no
cause of copper deficiency was identified.
The interval between upper gastrointestinal surgery and
symptom onset ranged from 5 to 26 years in the bariatric
group (mean 11.4 years, latencies reported in 8 of 9 cases),
and from 10 to 46 years in the non-bariatric group (mean
22.2 years, latencies reported in 12 of 17 cases). The dif-





















Fig. 1 Age at presentation. Female and male cases are plotted in
black and white, respectively
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(Mann–Whitney U test, p = 0.007). This analysis could
not be extended to other aetiologies as onset latencies were
less frequently reported and would have been impossible to
determine where the predisposing factor was clinically
silent.
Where haematological indices were reported, 78% (35
of 45 cases) showed at least one cytopenia. Anaemia was
the commonest cytopenia, being seen in 68% (30 of 44
cases). Nine cases were macrocytic, three were normocytic
and one was microcytic; no MCV was given in the
remaining cases. Leukopenia was seen in 50% (22 of 44
cases). Platelet count was only infrequently reported, but
was low in 3 of 15 cases.
Serum vitamin B12 levels at presentation were low in a
single case [29], but no further details were provided. In the
remaining cases, vitamin B12 levels at presentation were
either normal or high (44 cases) or not specified (10 cases).
These reports included 14 patients in whom B12 replace-
ment had previously been instigated either for a docu-
mented deficiency state or empirically despite normal
levels; in 10 of these, a lack of a haematological or neu-
rological response was described.
By definition, serum copper was low in all patients and
was below 0.1 lg/mL in 45% (25 cases). The distribution
of serum copper showed a pronounced skew towards very
low or undetectable serum copper (Fig. 2a). Caeruloplas-
min was low in all 40 cases in which it was reported (mean
reference range 21.5–48.1 mg/dL) and showed a similar
distribution (Fig. 2b) supporting the copper deficiency
state. A statistically significant correlation was seen
between serum copper and serum caeruloplasmin (Pearson
correlation coefficient 0.653, 2-tailed p \ 0.001). There
was a wide distribution of serum zinc values varying from
0.04 to 4.28 lg/mL (typical reference range 0.66–1.10 lg/
mL). Serum zinc was low in 20% (10 cases), normal in
31% (15 cases) and high in 49% (24 cases), and tended to
be higher in cases where zinc excess was reported as the
primary aetiology (range 1.36–4.28 lg/mL, median
2.00 lg/mL, mean 1.12 lg/mL in 9 cases attributed to zinc
excess; range 0.04–2.68 lg/mL, median 1.01 lg/mL, mean
1.12 lg/mL in 36 cases attributed to other aetiologies
where a numerical figure was given; Student’s t test for
different means, p \ 0.001; a further 4 cases only had a
qualitative description such as ‘‘normal’’ zinc levels).
There was a significant negative correlation between
serum copper and zinc (Fig. 3; Pearson correlation coeffi-
cient -0.327, 45 cases, 2-tailed p = 0.028). When cases
primarily attributed to zinc overload were excluded, this
correlation remained highly significant (Pearson correlation
coefficient -0.564, 36 cases, 2-tailed p \ 0.001).
Urinary copper excretion was typically low (50%, 13 of
26 cases) or normal (42%, 11 cases), but was elevated in 2
cases (8%). Urinary zinc was elevated in 81% (13 of 16
cases), sometimes by more than an order of magnitude
above the normal range. No correlation existed between
serum copper and urinary copper excretion (Pearson’s
correlation coefficient -0.083, 26 cases, 2-tailed
p = 0.688).
Table 1 Aetiology of copper deficiency
Primary cause Number of
cases (%)




Non-bariatric 17 Mesangioproliferative glomerulonephritis with high urinary
copper levels (1) [2], small intestine bacterial overgrowth
and denture cream use with normal serum zinc levels (1) [74]
[2, 4, 12, 13, 28, 38, 39, 41,
44, 47, 63, 74, 77, 88]
Bariatric 9 Zinc supplement use with normal serum zinc levels (1) [38, 39] [16, 29, 38, 39, 44, 47]
Zinc overload 9 (16%)
Denture cream 4 [58]
Supplements 2 [38, 44, 45, 67]
Haemodialysis 1 [89]
Unknown 2 Coeliac disease well-controlled on gluten-free diet (1) [19] [19, 24]
Malabsorption 8 (15%)
Coeliac disease 4 [21, 38, 44, 46]
Unknown 4 [30, 38, 44]
Iron supplements 1 (2%) [38, 41, 44]
Idiopathic 11 (20%) High serum zinc levels without reported
cause (7) [18, 38, 39, 41, 42, 44]
[1, 18, 38, 39, 41, 42, 44]
Cases are classified according to the reported primary cause. Any potential additional causes are also listed
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The results of spinal MRI scans were reported in 47 cases.
These were abnormal in 47% (22 cases), typically showing
increased T2 signal in the posterior cervical and thoracic
cord (Fig. 4).
Copper supplementation formed the mainstay of treat-
ment and was typically given orally (71%, 32 of 45 cases)
[1, 18, 19, 21, 24, 28, 30, 38, 39, 41, 42, 44–46, 63, 74, 77,
89] or intravenously with subsequent switching to the oral
route (20%, 9 of 45 cases) [12, 38, 41, 44, 47, 58, 67]. The
remaining patients received intravenous (4%, 2 cases) [71,
88], oral then intravenous (2%, 1 case) [38, 39, 44] or
intramuscular supplements (2%, 1 case) [4]; in 10 cases
(18%) the route of administration was not specified [13, 16,
29, 38, 39, 41, 44, 58]. Doses were usually equivalent to
2 mg/day of elemental copper, though administration of up
to 9 mg/day was reported (ignoring extreme outliers which
are likely to reflect reporting errors [89]). A variety of
copper salts were used, including copper acetate [63],
copper chloride [88], copper citrate [28], copper gluconate
[2, 12, 38, 44, 45, 74, 89], copper histidine [4] and copper
sulphate [1, 12, 38, 41, 44, 47, 67, 71, 77]. No adverse
effects were reported. Where possible, the presumed
underlying cause of copper deficiency was also treated. This
included stopping any exogenous supply of zinc [30, 38, 44,
45, 58, 67, 89] or iron [38], gluten-free diet for coeliac
disease [21, 38, 44, 46], gastric bypass revision [29], ste-
roids for mesangioproliferative glomerulonephritis [2] and
antibiotics for small bowel bacterial overgrowth [74].
Outcomes were stated in 47 cases. The neurological
deficit improved in 49% (23 cases), though two cases
continued to deteriorate neurologically until the dose of
copper supplementation was escalated (see below).
Descriptions of the improvements were usually scant and
ranged from subjective reductions in sensory symptoms to
objective improvements in spasticity, power and mobility;
there were no reports of full neurological recovery. In three
cases where spinal MRI had been abnormal at presentation,
repeated imaging after treatment showed improved
appearances [18, 40, 89]. In the other 51% (24 cases), the
neurological deficit stabilised. Where a haematological




Dietary intake and total body content
Copper is an essential dietary micronutrient, with a Rec-
































Fig. 2 Serum copper and caeruloplasmin. a In two cases, serum
copper was reported to be low with no numerical value given (not
shown). Typical reference ranges have a lower limit of normal of
0.75 lg/mL (range 0.65–0.85). b No readings were reported in 15
cases (not shown). The mean lower limit of normal was 21.5 mg/dL




















Fig. 3 Serum zinc against serum copper in the 45 cases where both
were reported. Different symbols represent different aetiologies
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Nutrient Intake (UK) [59] of 0.9 mg/day and 1.2 mg/day,
respectively. The average total copper content of the
human body is estimated at 75 mg (range 50–120 mg)
[69]. Particularly high levels are found in the brain, and this
probably applies to the spinal cord, too.
Absorption and excretion
Copper absorption occurs predominantly in the duodenum
[75, 76] and potentially also in the stomach [81]. Following
uptake via the apical membrane transporter Ctr1, whose
expression is regulated by copper status [48], copper is
transferred across the basolateral membrane by a P-type
ATPase (ATP7A), which is deficient in Menkes’ disease
[53], an inherited disorder of copper absorption. Intestinal
copper absorption can be inhibited by zinc and iron (see
below). In the portal circulation, copper is transported
bound to albumin and transcuprein. At the hepatocyte
level, it is incorporated into the enzymes superoxide dis-
mutase and cytochrome-c oxidase, or into the carrier pro-
tein caeruloplasmin for onward transport to systemic
tissues, where it is integrated into the numerous other
proteins described below [49]. Serum caeruloplasmin acts
as a marker of copper status: although its rate of synthesis
is unaffected by copper intake, caeruloplasmin lacking
bound copper has a short half-life in the serum and is
rapidly degraded [26].
When copper is found to be deficient, the serum levels are
usually very low with around half of cases having serum
copper levels below 0.1 lg/mL. This may reflect the
increasing likelihood of clinical presentation with the degree
of deficiency. The strong correlation between serum copper
and caeruloplasmin levels was in keeping with caerulo-
plasmin being an effective marker of copper status. How-
ever, caeruloplasmin is not essential for copper metabolism,
as a genetic deficiency (acaeruloplasminaemia) does not lead
to impaired systemic delivery of copper.
Excess copper is bound by metallothioneins, which are
upregulated to prevent toxicity. Copper is secreted into bile
via a P-type ATPase (ATP7B), which is lacking in
Wilson’s disease. Biliary excretion is the primary mode of
homeostasis, and chronic copper toxicity is unlikely in the
absence of a secretory deficit, either genetic (Wilson’s
disease) or acquired (hepatic failure) [17]. Although much
of the secreted copper is reabsorbed, 0.5–1.5 mg/day end
up in the faeces [49] and only a minute amount of copper
enters the urine (30–60 lg/day). In Wilson’s disease,
genetic deficiency of ATP7B impairs copper export into
bile and caeruloplasmin. Copper leaks into the serum and
urinary copper excretion is increased, making 24 h urinary
copper excretion a sensitive test for Wilson’s disease.
In 92% of cases, urinary copper was low or normal as
might be expected in a copper deficiency state. However,
two cases had an elevated urinary copper. In the first case
[2], the patient was diagnosed with membranoproliferative
glomerulonephritis in association with hepatitis C and had
a proteinuria of 3.798 g/24 h. Both the cupriuria and a
remote history of non-bariatric upper gastrointestinal sur-
gery were felt to contribute to the copper deficiency state.
The second case [12] had only a marginally elevated 24 h
urinary copper. Renal function was not reported and there
was no mention of renal impairment or conditions which
could impair kidney function. Although the kidneys might
be expected to conserve copper in a deficiency state, daily
excretion of copper in the urine is an order of magnitude
less than that in the faeces and thus normally has little
bearing on serum copper. Hence, the lack of correlation
between serum copper and urinary copper excretion is less
surprising.
Systemic roles
Copper is a transition metal possessing two physiological
oxidation states—reduced Cu1? (cuprous) and oxidised
Cu2? (cupric)—and can thus act as an intermediary for
electron transfer in redox reactions. It is involved in the
catalytic function of several key enzymes [82], mostly
oxidoreductases and monooxygenases, whose diverse
Fig. 4 Sagittal and axial T2-
weighted 3T MR images of the
cervical cord. A typical high
signal lesion is demonstrated in
the dorsal columns
(arrowheads)
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metabolic roles are summarised in Table 2. Copper can
regulate gene expression through copper-responsive tran-
scription factors [79], and is known to upregulate the genes
encoding superoxide dismutase and proteins involved in
cellular copper storage and partitioning [82]. Moreover,
metal-responsive elements have been found in all eukary-
otic metallothionein promoters.
Mechanisms of acquired deficiency
Upper gastrointestinal surgery
Certain types of upper gastrointestinal surgery can reduce
the effective absorption area for particular micronutrients.
Deficiencies of iron and vitamin B12 are especially com-
mon [15, 54, 80], with a lack of intrinsic factor contributing
to the latter. Whilst neurological complications of
gastrectomy for peptic ulcer disease have long been
recognised, the underlying aetiology often remained
obscure [38, 39]. The association between a remote history
of upper gastrointestinal surgery, copper deficiency and
myelopathy was first described in 2001 [71], and has since
been increasingly reported following both non-bariatric [2,
4, 12, 13, 28, 38, 39, 41, 44, 47, 63, 74, 77, 88] and bari-
atric intervention [16, 29, 38, 39, 44, 47].
Partial gastrectomy has rarely been used to treat peptic
ulcer disease since the advent of effective pharmacological
therapy. The number of cases of gastrectomy-related CDM
is small relative to the number of past procedures. How-
ever, it is likely that many further cases will be diagnosed
because undiagnosed hypocupraemia is common in
patients with a history of gastrectomy [64], CDM may
manifest over 40 years after the operation [28, 41] and
awareness amongst physicians continues to increase.
Table 2 Copper-dependent enzymes
Group Enzyme Role
Oxidoreductases Amine oxidase, flavin-containing (amine
oxidase, monoamine oxidase, tyramine
oxidase)
Metabolism of neurotransmitters—noradrenaline,




Metabolism of amines—histamine, putrescine,
cadaverine








Antioxidant and free radical scavenging—
conversion of superoxide radicals to hydrogen
peroxide
Ferroxidase I (caeruloplasmin) Iron transport—oxidation of Fe2? to Fe3? to enable
serum transport on transferrin
Copper storage and transport
Antioxidant and free radical scavenger
Ferroxidase II Iron transport—oxidation of Fe2? to Fe3? to enable
serum transport on transferrin
Hephaestin (ferroxidase) Iron transport—oxidation of Fe2? to Fe3? in
intestinal cells to enable iron uptake
Monooxygenases Dopamine beta-monooxygenase
(dopamine beta-hydroxylase)





Peptide hormone maturation—amidation of alpha-
terminal carboxylic acid group of glycine
Monophenol monooxygenase
(monophenol oxidase, tyrosinase)
Melanin synthesis—conversion of tyrosine to DOPA
Methylation cycle (potentially) Methionine synthase
(5-methyltetrahydrofolate-
homocysteine S-methyltransferase)
Transfer of methyl group from
methyltetrahydrofolate to homocysteine to
generate methionine for the methylation cycle and
tetrahydrofolate for purine synthesis
Adenosylhomocysteinase
(S-adenosylhomocysteine hydrolase)
Regeneration of homocysteine from
adenosylhomocysteine in the methylation cycle
Copper is a co-factor in a range of oxidoreductases and monooxygenases, and may also have a regulatory role for two enzymes in the methylation
cycle. Each enzyme is listed with its recommended name, other common names and biological role. Adapted from [87] with permission
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The annual number of bariatric operations continues to
grow [15, 55], with the commonest procedure being a
Roux-en-Y gastric bypass. Post-operatively, food bypasses
most of the stomach and the entire duodenum. CDM tends
to develop sooner after bariatric than after non-bariatric
operations, probably due to the greater reduction in the
effective absorption area for copper. Case numbers of
CDM will rise with the growing use of bariatric surgery
and with the ageing of the present cohort.
Malabsorption
In half the cases of CDM attributed to malabsorption,
coeliac disease was diagnosed; in the other half, no cause
of malabsorption was established. In three cases of idio-
pathic copper malabsorption, no detailed investigation
findings were reported [38, 44]. In the fourth case,
malabsorption was not specific to copper: the patient was
cachectic and exhibited concomitant deficiencies of iron,
vitamin D and vitamin E. A D-xylose absorption test was
compatible with proximal intestinal malabsorption, but
upper gastrointestinal endoscopy, duodenal biopsies and
faecal microbiology failed to identify an underlying cause
[30].
Zinc excess
Zinc upregulates the expression of the chelator metallo-
thionein in enterocytes. Copper has a higher affinity for
metallothionein than zinc, and remains bound in the en-
terocytes which are sloughed into the lumen and elimi-
nated. This mechanism is exploited therapeutically when
using zinc to achieve a negative copper balance in Wilson’s
disease [91].
It is estimated that 7–15% of denture wearers use
adhesives [8], many of which contain zinc in significant
concentrations, leading to potentially excessive daily zinc
intakes [58]. The use of denture cream may not be covered
in routine history taking and should be specifically exclu-
ded when a state of zinc excess has been established. In
dialysis patients, oversubstitution of zinc through the
dialysate should be considered, especially since this
mechanism may be unknown to non-nephrologists. Where
zinc overload was attributed to the use of supplements, the
dose (200–400 mg/day) considerably exceeded the tolera-
ble upper intake level of 40 mg/day (US) [14].
In two cases of CDM, zinc excess was evidenced by
high zinc levels in serum samples and 24 h urine collec-
tions, but no cause could be identified [19, 24]. After
instituting adequate copper supplementation, the patients
stabilised neurologically and their serum copper levels
improved or normalised, but zinc levels remained high in
serum and urine. We are not aware that a similar
neurological syndrome has been clearly attributed to
hyperzincaemia without hypocupraemia. This suggests that
the neurological deficit was caused by copper deficiency,
which in turn was probably secondary to zinc excess.
The first case of CDM due to idiopathic zinc excess was
found to have elevation of urinary zinc excretion (approx.
10 times the upper limit of normal, ULN) and serum zinc
(approx. 1.5 times the ULN) although the zinc content of a
liver biopsy specimen was normal [24]. Since no external
source of zinc excess could be identified, the authors
hypothesised that increased absorption or decreased
excretion of zinc in the intestine might be responsible. To
address a potential genetic cause, all living first degree
relatives underwent neurological examination as well as
serum copper and zinc assays, all of which were normal.
In the second case, the high ratio of urinary zinc
excretion (up to 20 times the ULN) to serum zinc (approx.
1–2 times the ULN) was interpreted as indicating primary
zinc toxicity [19]. Since 60–90% of zinc excretion is
gastrointestinal [37], the continued urinary excretion of
up to 20 mg/day implied either an ongoing intake of
50–200 mg/day, or previous massive body overload. As no
external source of zinc was identified and zinc stool content
could not be assayed, these possibilities could not be
distinguished.
A negative correlation between serum zinc and serum
copper would be expected in patients with zinc overload.
However, high serum and/or urinary zinc levels were also
reported in other aetiologies, including idiopathic cases.
There was a negative correlation between serum zinc and
serum copper across all patients, which persisted even
when cases attributed to zinc overload were excluded. It
remained unclear whether elevated zinc levels may have
contributed to hypocupraemia in patients not considered to
have primary zinc overload. High serum zinc concentra-
tions can be seen as a heritable trait without any overt
clinical manifestations [73], and might therefore represent
an epiphenomenon.
Urinary zinc levels did not show a consistent pattern. Of
those patients with high urinary zinc excretion, only seven
had raised serum zinc levels with the other six having
normal or even low serum zinc levels. It is possible that
increased zinc excretion represents a homeostatic mecha-
nism to maintain a normal serum zinc level in the face of
external zinc intake.
Iron supplements
In one case [38, 41, 44], CDM was potentially related to
the use of iron supplements. Neurological symptoms began
1 year after starting ferrous sulphate at 975 mg per day for
anaemia of unclear cause. Vitamin B12 levels were bor-
derline low, but methylmalonic acid levels were normal
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and neurological deterioration continued despite vitamin
B12 replacement. When copper deficiency was detected,
copper replacement was instituted and iron supplements
were stopped. There was neurological improvement but the
haematological outcome was not reported.
It was suggested that excess iron intake may have con-
tributed to the hypocupraemia, and such an association has
been described in animals [33, 72, 90] and in infants [23,
50, 57]. However, it is conceivable that her original
anaemia could have been due to copper deficiency which
was recognised only after neurological features developed.
Idiopathic
In two patients with idiopathic CDM, colonic biopsies were
taken and copper content was found to be significantly
increased [39]. This suggested that impaired mobilisation
from the intestinal mucosa might contribute to the systemic
deficiency state in some patients. Impaired copper transport
across the basolateral membrane occurs in Menkes’ disease
and leads to increased copper content in duodenal mucosa
[10], but sequencing of the ATP7A gene in one case of
idiopathic CDM did not show any abnormalities [43].
Although alterations in the promoter or other non-coding
regions as well as large intragenic deletions could not be
ruled out, this finding militates against ATP7A mutations
contributing to hypocupraemia in idiopathic CDM. It
remains possible that mutations in other copper transport-
ers or chaperones play a role. Such mutations might also
explain why CDM afflicts only a minority of patients with
a comparatively prevalent risk factor such as previous
upper gastrointestinal surgery.
Effects of copper deficiency
Copper deficiency may manifest in multiple organ systems.
Haematological effects
It was found in the 1930s that copper is vital for effective
erythropoiesis [56]. The haematological manifestations of
deficiency are typically anaemia or neutropenia, or more
rarely pancytopenia [85]. The anaemia is usually normo-
cytic or macrocytic, but may rarely be microcytic. A retro-
spective review of 40 patients with copper deficiency
defined the typical bone marrow findings of hypocellular-
ity, vacuolisation of granulocyte and erythroid precursors,
iron-containing plasma cells and ring sideroblasts [22].
Owing to the similarity of the haematological findings,
copper deficiency may be mistaken for a myelodysplastic
syndrome. Some haematology textbooks do not list copper
deficiency as a differential of myelodysplastic syndrome
[20], and in cases with concomitant myelopathy the
neurologist may be the first to consider copper deficiency
as the unifying diagnosis.
The mechanisms underlying the haematological effects
of copper deficiency have not been fully elucidated. The
anaemia appears to be partly attributable to impaired iron
metabolism. Copper is an essential component of both
caeruloplasmin and hephaestin, which are necessary for
normal iron homeostasis. Both have enzymatic activity as
ferroxidases and are involved in iron export from non-
intestinal [27] and intestinal cells [61], respectively. In
copper deficiency, iron is seen to accumulate in the liver
and can be released by intravenous caeruloplasmin.
Although the literature suggests that copper deficiency
typically causes a microcytic anaemia akin to iron defi-
ciency, this pattern was reported in only one of the cases
reviewed herein. The remaining cases where MCV was
reported were either macrocytic (9 cases) or normocytic
(3 cases). The difference between copper deficiency and
iron deficiency anaemia may be due to iron utilisation
being impaired only at certain steps or the contribution of
other mechanisms. For example, copper deficiency seems
to impair the production of haem from ferric iron and
protoporphyrin, possibly because decreased energy pro-
duction (cytochrome-c oxidase) in erythrocytes impinges
on the synthetic pathway [49]. In addition, alterations in
erythrocyte membrane fluidity and oxidative damage
cause reduced red cell lifespan in copper-deficient rats
[66].
Suggestions for the mechanism leading to neutropenia
include destruction of myeloid precursors and impaired
maturation within the bone marrow, impaired release of
mature neutrophils from the bone marrow and increased
serum clearance of neutrophils [60]. Indeed, the bone
marrow of copper-deficient patients contains a decreased
number of myeloid precursors which show vacuolisation
[22].
Neurological effects
Whilst copper deficiency in utero leads to impaired neu-
rodevelopment and neurodegeneration [31], acquired
copper deficiency in adults has been reported to have a
range of neurological manifestations. Myelopathy is by
far the commonest association, and is clinically and
radiologically indistinguishable from SCD [40, 44]. It has
been suggested that CDM is caused by dysfunction of
cytochrome-c oxidase [38], which is known to be copper-
dependent. This is potentially supported by the high CSF
lactate levels found in one case [30]. However, cyto-
chrome-c oxidase is not vitamin B12-dependent, so this
hypothesis fails to explain the phenotypic parallels
between CDM and SCD. We have previously proposed
that dysfunction of the methylation cycle is the first step
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in a final common pathway of CDM and SCD [87]. This
cycle catalyses the net transfer of a methyl group from
methyltetrahydrofolate to a variety of macromolecules,
including myelin proteins. SCD is known to be caused by
dysfunction of methionine synthase, which is a key part
of the cycle. Methionine synthase and another enzyme
involved in the cycle, S-adenosylhomocysteine hydrolase,
may depend on copper. This theory could therefore
explain the clinical and radiological congruence between
CDM and SCD, but it remains to be proven with direct
biochemical evidence.
It was recently noted that subacute myelo-optico-neu-
ropathy (SMON) bears significant phenotypic similarities
to CDM, and deranged copper homeostasis may have a
dominant role in its pathogenesis [70]. Almost 10,000
cases of SMON in Japan are thought to have been caused
by clioquinol until its use was banned in 1970. Clioquinol
was originally developed as an antimicrobial and acts as a
metal chelator and possibly an ionophore. Despite
decades of intense research, the mechanism underlying
SMON was never conclusively identified. There is
renewed interest in clioquinol as a treatment for Alzhei-
mer’s disease and cancer [5]. It would therefore be
desirable to clarify the role of copper in SMON in an
animal model [70], and a range of safety precautions has
been proposed to minimise the risk of SMON in clinical
studies [51].
Optic neuropathy in SMON was variable and often
subclinical [70, 78]. Visual disturbance was not reported in
cases of CDM, but optic neuropathy has been described in
association with copper deficiency [20, 74]. It is therefore
possible that subtle visual dysfunction might accompany
some cases of CDM, and might only be detected on careful
clinical examination, including assessment of colour
vision.
A previous series of 25 cases of CDM found that spinal
MRI was significantly abnormal in 44% [40], which is in
agreement with the figure of 47% reported herein. Both
studies also concur that the most consistent finding is a
segment of high T2 signal in the dorsal midline cervical
and thoracic cord.
Whilst neurophysiological data were not reviewed here,
the largest series published to date reported an axonal
peripheral neuropathy in 21 of 24 patients tested, with
mixed sensory/motor involvement in 11 cases [38].
Somatosensory potentials were abnormal in all 20 patients
who underwent testing, with impaired central conduction
implicated in 19 of them.
Other effects
The first inherited defect of copper transport, Menkes’
disease, was described in the 1960s [53]. The low serum
copper causes malfunction of essential copper-dependent
enzymes manifesting as impaired growth, brittle or kinky
hair (monoamine oxidase), skin and hair hypopigmentation
(tyrosinase), hypothermia (cytochrome-c oxidase) and
arterial fragility (lysyl oxidase) [52]. Affected infants
develop severe neurodegeneration with deficient myelina-
tion and cerebellar and cerebral atrophy seen on MRI. The
condition is fatal in infancy and does not respond to sys-
temic copper treatment as ATP7A is necessary for copper
uptake into the central nervous system [36].
Acquired copper deficiency in childhood may also cause
skeletal abnormalities [25], hypopigmented hair and
hypotonia [9], impaired growth [7] and immunity [6, 32].
In adults, copper deficiency can adversely affect choles-




Nearly all aetiologies of CDM involve a reduction in
gastrointestinal copper absorption. Nonetheless, oral
copper supplementation is efficacious and affords an
acceptable and practical mode of therapy. In some cases,
oral maintenance therapy was preceded by parenteral
supplementation, presumably in order to rapidly replenish
copper stores and avert any further deterioration. Although
some reports refer to parenteral treatment only [4, 71, 88],
the efficacy of oral supplements should make prolonged
parenteral therapy unnecessary.
Typical daily doses were equivalent to 2–4 mg of ele-
mental copper. In one case attributed to non-bariatric
gastrointestinal surgery, administration of 2 mg of oral
copper per day normalised blood parameters and improved
neurological symptoms. However, a subsequent symp-
tomatic and biochemical relapse necessitated that the dose
be incremented to 4 mg and then 6 mg, which achieved
sustained remission [63]. Another patient with idiopathic
zinc overload was poorly compliant with oral copper sup-
plementation at 2 mg/day. His serum copper levels
remained low and the neurological deficit progressed,
though serum caeruloplasmin increased to a value at the
low end of the normal range and the anaemia resolved. The
copper dose was gradually escalated to 8 mg/day but
compliance remained poor and he continued to deteriorate
neurologically. Subsequently, the patient reported better
compliance and his neurological status improved. How-
ever, his highest recorded serum copper level remained
below the normal range, and it was unclear whether this
reflected insufficient dosage, poor compliance or other
factors. Copper doses of up to 9 mg per day have been
reported [2].
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Therapeutic efficacy does not appear to be influenced by
the type of copper compound administered. Oral copper
gluconate did not influence serum copper levels in normal
volunteers [62]. Whilst this finding was previously inter-
preted as signifying poor bioavailability [38, 88], it appears
to merely reflect intact copper homeostasis through biliary
excretion in a copper-replete study population.
Since zinc can interfere with copper absorption, care
must be taken to avoid copper preparations that also con-
tain significant quantities of zinc, as may be the case with
multivitamin tablets. We have encountered difficulties in
sourcing pharmaceutical-grade copper-only supplements in
the UK, and currently use an amino acid chelate of copper
that can be obtained from health food retailers (Solgar
copper amino acid chelate, available via http://www.solgar.
co.uk) pending local availability of a dedicated formula-
tion. We would suggest that the underlying cause should be
treated if possible, and that oral supplementation equiva-
lent to 8 mg of elemental copper per day should usually
suffice. A brief course (e.g. for 5 days) of parenteral ther-
apy may be considered to hasten normalisation of body
copper stores before switching to the oral route. Lower
doses are typically successful and may reduce the cost and
number of tablets required, but carry a small risk of failing
to prevent neurological progression. A dose of 8 mg/day,
combined with an average diet, is unlikely to exceed the
tolerable upper intake level of 10 mg/day (US) [14]) or the
provisional maximum tolerable daily intake of 0.5 mg/kg/
day (World Health Organisation [68]). Furthermore, bio-
availability is lessened by the absorptive defects which
underlie CDM, and the continued integrity of copper
homeostasis through biliary excretion should prevent a
state of chronic copper excess [17].
Treatment may need to be continued indefinitely where
the underlying risk factor cannot be eliminated. Regular
follow-up is necessary to ensure normalisation of bio-
chemical and haematological parameters and stabilisation
or improvement of neurological features.
Prevention
Following bariatric surgery, patients remain under follow-
up for years, and if copper were included amongst the
micronutrients that are already assayed at regular intervals,
any deficiency could potentially be corrected at a pre-
symptomatic stage. Patients with most other risk factors,
including past non-bariatric upper gastrointestinal surgery,
are unlikely to have ongoing follow-up arrangements.
Physician vigilance therefore remains paramount for
making an early diagnosis. There is probably no role for
prophylactic copper supplementation, since most risk fac-
tors for copper deficiency are relatively prevalent yet only
carry a low risk of CDM. Except for the avoidance of
excessive zinc supplementation, primary risk factor modi-
fication does not appear realistic.
Outcome
Whilst treatment causes prompt and full resolution of
haematological abnormalities, the neurological deficit
merely stabilises or partially improves. Hence, it is crucial
to avoid delays in diagnosis and treatment to avert poten-
tially irreversible neurological deterioration.
We would suggest that serum copper and caeruloplas-
min levels should be first line tests in patients presenting
with a phenotype suggestive of SCD, especially if risk
factors for copper deficiency or cytopenias are present. In
other non-compressive myelopathies, these tests should be
considered early as they may identify copper deficiency as
a treatable aetiology. Due to the lack of a gold standard
test, the sensitivity and specificity of these tests is
unknown.
Future avenues
Advances in the understanding of the pathophysiology of
CDM may yield further therapeutic approaches in the
future. For example, if dysfunction of the methylation
cycle were confirmed as the pathological mechanism
underlying CDM, methionine and betaine supplementation
might help to restore normal function of this cycle [87].
Conclusion
CDM should be considered as a differential in the work-up
of non-compressive myelopathies, and a compatible clini-
cal picture combined with low serum copper and caerulo-
plasmin establishes the diagnosis. Diagnostic pointers
include cytopenias and predisposing factors. Anaemia and
leukopenia are seen in 68 and 50% of cases, respectively,
and a diagnosis of myelodysplastic syndrome may have
been made previously. Risk factors for CDM reduce the
effective absorption area for copper and include previous
upper gastrointestinal surgery (47% of cases); zinc over-
load (16%) through denture cream, supplements or hae-
modialysis; and malabsorption (15%). The role of iron
supplements in causing CDM (2%) is unclear, as is the role
of high serum or urinary zinc in patients not deemed to
have zinc overload.
The clinical and radiological phenotype closely mimics
SCD. Spinal MRI is abnormal in 47% of cases, typically
showing a longitudinal high T2 signal lesion in the dorsal
cervical and thoracic cord. Dysfunction of the methylation
cycle is a potential pathophysiological substrate explaining
the phenotypic similarity between SCD and CDM.
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Reported associations of copper deficiency with other
neurological manifestations require further study.
Treatment involves copper supplementation and
management of any underlying risk factors. With replen-
ishment of copper, haematological abnormalities resolve
rapidly and completely. By contrast, neurological deficits
merely stabilise (51% of cases) or partially improve (49%).
Hence, early recognition of CDM is vital to avert
irreversible deterioration. After bariatric surgery, which is
likely to become the commonest risk factor, surveillance of
copper levels or prophylactic supplementation could also
help to avoid copper deficiency and thus CDM.
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